{"id":649531,"date":"2023-04-27T21:08:01","date_gmt":"2023-04-27T21:08:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=649531"},"modified":"2023-04-27T21:08:01","modified_gmt":"2023-04-27T21:08:01","slug":"cerebral-amyloid-angiopathy-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-alnylam-pharmaceuticals-amydis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cerebral-amyloid-angiopathy-market-to-exhibit-substantial-growth-rate-during-the-forecast-period-20222032-delveinsight-key-companies-alnylam-pharmaceuticals-amydis_649531.html","title":{"rendered":"Cerebral Amyloid Angiopathy Market to Exhibit Substantial Growth Rate During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Alnylam Pharmaceuticals, Amydis"},"content":{"rendered":"
\n
\"Cerebral<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Cerebral Amyloid Angiopathy is expected to grow owing to the increasing prevalence of dementia, the rise in the elderly population, and the launch of pipeline therapies in the market.<\/div>\n

DelveInsight’s “Cerebral Amyloid Angiopathy Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cerebral Amyloid Angiopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The Cerebral Amyloid Angiopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Cerebral<\/p>\n

Cerebral Amyloid Angiopathy: An Overview<\/strong><\/p>\n

Cerebral Amyloid Angiopathy (CAA), also called cerebrovascular amyloidosis, is a cerebrovascular disorder caused by the accumulation of cerebral amyloid-β (Aβ) in the tunica media and adventitia of leptomeningeal and cortical vessels of the brain. The resultant vascular fragility tends to manifest in normotensive elderly patients as lobar intracerebral hemorrhage. It is a common cerebral amyloid deposition disease, affecting ~90% of Alzheimer’s patients and increasing the risk of stroke, brain hemorrhage, or dementia.<\/p>\n

The exact etiology of CAA is not fully understood. It is characterized by congophilic material (amyloid-beta 40 peptides) being deposited into the leptomeninges and small to medium-sized cerebral blood vessels. This deposition weakens vessel walls, making them prone to bleeding. CAA can occur in certain familial syndromes or can occur sporadically.<\/p>\n

The most common type of CAA is caused by amyloid beta-protein (Abeta), which is particularly associated with Alzheimer’s disease (AD).<\/strong><\/em><\/p>\n

Cerebral Amyloid Angiopathy Market Key Facts<\/strong><\/p>\n